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Abstract
Although scientific advances have resulted in significantly improved survival among lymphoma patients, 
certain subsets of lymphoma patients still have poor prognosis, which includes relapsed and treatment 
refractory patients. Brentuximab vedotin, an anti-CD30 targeted therapy has shown remarkable results given 
in both Hodgkin and non-Hodgkin lymphoma, even in cases without CD30 expression. Unfortunately, 
evidence of its effectiveness in Indonesian patient is still limited as there is only 1 case report of such subject 
published. 
Conclusion: Brentuximab vedotin, an anti-CD30 targeted therapy presents as an effective therapeutic 
option for relapsed and treatment refractory lymphoma patients.
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Abstrak
Perkembangan ilmu pengetahuan telah berdampak pada peningkatan kesintasan secara signifikan pada pasien 
limfoma. Akan tetapi, masih terdapat sebagian pasien yang memiliki kesintasan buruk, termasuk pasien yang 
kambuh dan pasien yang refrakter terhadap terapi. Brentuximab vedotin, obat terapi target anti-CD30, 
menunjukkan hasil yang luar biasa bila diberikan baik pada pasien limfoma Hodgkin maupun non-Hodgkin, 
bahkan pada kasus – kasus yang tidak mengekspresikan reseptor CD30. Sayangnya, hingga saat ini bukti klinis 
efektivitas obat ini pada populasi Indonesia masih terbatas dan hingga saat ini baru terdapat 1 laporan kasus 
mengenai penggunaan obat tersebut pada pasien di Indonesia.
Kesimpulan: Brentuximab vedotin, obat terapi target anti-CD30, merupakan pilihan terapi yang efektif pada 
pasien limfoma yang kambuh serta pasien yang refrakter terhadap terapi
Kata Kunci: Lymphoma, brentuximab, CD30, Indonesia
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Introduction
Lymphoma, a heterogenous group of 
neoplasms originating from lymphoid organs, 
is responsible for 3.2% of all cancer cases and 
225,000 cancer-related mortality annually 
worldwide. 1 Scientific advances have resulted 
in significantly improved survival among 
lymphoma patients with 5-year OS reported 
to be around 67-98% for Hodgkin lymphoma 
(HL) and 4-year OS ranging from 55% to 
94% for non-Hodgkin lymphoma (NHL).2,3 
Although generally associated with good 
prognosis, some subsets of lymphoma patients 
still have poor prognosis, which includes 
relapsed and treatment refractory patients.4 
More effective treatment modalities are needed 
in these patient subsets, especially for patients 
who are not suitable to receive autologous stem 
cell transplant. Brentuximab vedotin, an anti-
CD30 targeted therapy presents as an effective 
therapeutic option for these patients.
CD30 in Lymphoma
CD30 is expressed in 14-25% of B cell 
lymphoid malignancies and 90% of T cell 
lymphoid malignancies. 5,6,7 Overexpression of 
CD30 contributes towards lymphomagenesis 
through anti-apoptotic mechanism, resulting 
in cell survival.8 Inhibition of CD30 by 
brentuximab vedotin has been proven to be 
efficacious in lymphoma patients expressing 
CD30, both in HL and NHL. 
Brentuximab Vedotin in Hodgkin 
Lymphoma
First significant result came from a phase 
2 study by Younes et al, which demonstrated 
75% ORR in relapsed or refractory HL 
patients with 34% patients experiencing 
complete remission.9 Similarly, positive result 
was also observed in a phase 3 AETHERA 
trial assessing the effectiveness of brentuximab 
vedotin given as early consolidation after 
autologous stem-cell transplantation. In this 
trial, brentuximab arm showed significantly 
improved progression-free survival (PFS), 
with a stratified hazard rate (HR) of 0.57, 
equivalent to a 43% reduction in the HR for 
PFS. The median PFS in the brentuximab 
arm was 42.9 months vs. 24.1 months in the 
placebo arm.10  Both trials showed manageable 
safety profile with peripheral neuropathy and 
neutropenia reported to be the most common 
side effects.9,11 Given as combination with 
gemcitabine, 57% of pediatric and young adult 
patients with relapsed or refractory HL showed 
complete response within the first four cycles 
of treatment and 31% patients experienced 
partial response or stable disease after cycle 4.12
Positive results in relapsed or refractory HL 
patients lead to trials to incorporate brentuximab 
vedotin as first-line treatment in combination 
with existing modalities. A phase 2 trial by 
Abramson et al, assessed the effectiveness of 
brentuximab vedotin in combination with 
adriamycin, vinblastine and dacarbazine (A-AVD) 
in 34 patients. At the end of treatment, 30 
patients (88%) were in complete remission 
(CR), although side effects are observed to be 
worse than generally expected in AVD treatment 
alone. 13 Similarly, Kumar et al observed 93.3% 
1-year PFS in early stage unfavorable risk HL 
patients given A-AVD followed by involved-site 
radiotherapy.14 Compared to standard ABVD 
(doxorubicin, bleomycin, vinblastine, and 
dacarbazine) regimen, A-AVD is associated with 
better 2-year PFS (82.1 vs. 77.2%) as first-line 
treatment in stage 3-4 HL patients.15 Brentuximab 
vedotin is also observed to be similarly effective 
given in combination with other chemotherapy 
regimen. Eichenauer et al reported CR of 94% 
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(46/49 patients) in advanced HL patients 
receiving BrECAPP (brentuximab vedotin, 
etoposide, doxorubicin, cyclophosphamide, 
procarbazine, and prednisone) and 88% 
CR (46/53 patients) in patients receiving 
BrECADD (brentuximab vedotin, etoposide, 
doxorubicin, cyclophosphamide, dacarbazine, 
and dexamethasone) as their final treatment 
outcome, although 58 serious adverse events 
were reported, 32 events in 21 of 50 patients 
who received BrECAPP and 26 events in 18 
of 52 patients who received BrECADD.16 
Brentuximab vedotin also presents as a unique 
option for patients unsuitable for standard 
chemotherapy. Gibb et al observed 84% objective 
response rate (ORR) in this patient segment given 
2-16 cycles (median 4) of brentuximab vedotin 
monotherapy. 17
Brentuximab Vedotin in non-Hodgkin 
Lymphoma
Commonly used in treating HL, 
brentuximab vedotin has shown modest 
activity in NHL patients expressing CD30. 
Jacobsen et al observed ORR of 44% for 
relapsed/refractory diffuse large B-cell 
lymphoma (DLBCL) patients, including 
17% CR (8 patients).18 Given in combination 
with RCHOP as first-line treatment in 
CD30-unselected high-intermediate/high-risk 
DLBCL patients, Yasenchak et al observed 
ORR of 92% (11/12 patients), with 7 CR 
(58%), 4 partial remission (PR) (33%), and 
1 progressive disease (PD), elucidating the 
potential of brentuximab vedotin in treating 
certain NHL patients .19
Brentuximab Vedotin in Indonesia
Currently, evidence of BV effectiveness in 
Indonesian patients is still extremely limited, 
as there is only 1 case report of such subject 
published. Purwanto et al reported a case of 
complete remission in a 40-year-old Asian 
female with heavily treated relapsed Hodgkin’s 
lymphoma showed complete remission (CR) 
who received 8 cycles of BV in combination 
with gemcitabine as 4th line treatment, however 
in this report the patient’s CD30 status was 
unknown.20 Regardless, BV is observed to show 
activity even in CD30 negative lymphomas, 
suggesting its potential mechanism of action 
beyond CD30 inhibition. 21
An observational retrospective study 
recently reported that CD30 is expressed in 
30% (14/42) of Indonesian HL patients and 
100% (3/3) in systemic anaplastic large cell 
lymphoma (sALCL) patients, suggesting its 
potential as a target for therapy in Indonesian 
population. 22 Despite its promising potential, 
widespread use of brentuximab vedotin in 
Indonesia might be challenging for 2 reasons. 
Firstly, examination of CD30 expression is 
not yet widely available across Indonesia. 
Secondly, brentuximab vedotin is currently 
not covered by Indonesian national insurance. 
Its high price tag may not be affordable by 
most of Indonesian population without the 
support of private health insurance. Clinical 
trial on Indonesian population is needed to 
provide evidence to support national coverage 
of brentuximab vedotin for the treatment of 
lymphoma patients in Indonesia.
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